Background India accounts for a disproportionate burden of global childhood illnesses. To inform policies and measure progress towards achieving child health targets, we estimated the annual national and state-specific childhood mortality and morbidity attributable to Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) between 2000 and 2015.
Introduction
Streptococcus pneumoniae (pneumococcus) and Haemo philus influenzae type b (Hib) are serious causes of pneu monia, meningitis, and other severe childhood infections in India and worldwide. 1 Highly efficacious vaccines that provide protection from these pathogens have been used in developed and developing countries for many years; global data on vaccine introduction and vaccine programme implementation can be visualised on VIEWhub, an interactive platform developed by the International Vaccine Access Center (IVAC). The Hib containing pentavalent vaccine was introduced in the immunisation programmes of Tamil Nadu and Kerala in December, 2011. 2 It is now used in the routine immun isa tion programme of all states in India. The 13valent pneumococcal conjugate vaccine (PCV) was introduced subnationally in 2017. There are plans to expand its use in India in the coming years.
Efforts to improve access to primary maternal and child health services in India have contributed to progress towards reducing child mortality. Many of these efforts have been concentrated in less socioeconomically developed states, including those that comprise the Empowered Action Group (EAG). Although India narrowly missed the Millennium Development Goal child mortality target of 44 deaths per 1000 livebirths by 2015, 3 imple mentation and widespread use of new child health interventions, including new vaccines that protect children from some of the leading causes of mortality, could accelerate achievement of the Sustainable Development Goal of 25 child deaths per 1000 livebirths or lower in India by 2030. Since around 20% of child deaths occur in India, global progress towards reducing child mortality will depend on progress in India.
Disease burden is an important decisionmaking factor for the introduction and sustained use of new vaccines. The technical challenges associated with doing observa tional surveillance studies for pneumococcal and Hib infections in resourcepoor settings have been extensively documented. 4, 5 Models can provide comple mentary insight into disease burden when observational studies are absent, inconsistent, or unable to provide such information for epidemiological reasons. For large and diverse countries such as India, subnational disease burden estimates are particularly important for policy making and programme planning, as national burden estimates can mask sub stantial variation in morbidity and mortality across large subnational populations.
Researchers have estimated that there were around 105 000 deaths from pneumococcal pneumonia and 564 000 cases of severe pneumococcal pneumonia in 2010 in children younger than 5 years in India. 6 There are no published subnational burden estimates for clinical pneumococcal pneumonia, pneumococcal meningitis, or other invasive pneumococcal diseases. There are also no published subnational burden estimates for Hib infection. In light of widespread Hib vaccine use, the anticipated expansion of PCV use in India, and reduct ions in allcause mortality since 2010, we aimed to pre pare statelevel pneumococcal and Hib disease burden estimates for India from 2000 to 2015.
Methods

Overview
In this modelling study, we estimated the pathogen specific burden in children aged 1-59 months at the state level separately for each of the three clinical syndromes associ ated with pneumococcus and Hib (ie, pneumonia, men ingitis, and invasive nonpneumonia, nonmeningitis [NPNM]) using methods briefly described here and in detail elsewhere. 1 NPNM is characterised by the isolation of pneumococcus or Hib from normally sterile body fluid but without the clinical findings of pneumonia or menin gitis. Input data for each model are described in table 1. [7] [8] [9] [10] [11] [12] [13] [14] [15] As previously reported, 1 we updated a systematic review of pneumococcal and Hib invasive disease 16 with published and unpublished data up to and including 2014 for the pathogenspecific meningitis and NPNM models. We searched six global databases (ie, PubMed, Embase, Biosis, Cochrane, Global Health, and Pascal) and five regional databases (ie, IMEMR, IMSEAR, LILACS, WHOLIS, and WPRIM) and followed the same quality assessment criteria described in the original literature review. 16 
Research in context
Evidence before this study We 
Added value of this study
We present, to our knowledge, the first comprehensive subnational estimates of pneumococcal and Hib morbidity and mortality in children aged 1-59 months in India, due to all syndromes associated with these pathogens (ie, pneumonia, meningitis, and other invasive diseases). This study is also the first to report on the annual subnational pneumococcal and Hib disease burden from 2000 to 2015. These estimates are based on recently published subnational cause of death estimates for India and incorporate new data from 67 studies published between 2006 and 2014, including three studies from India. These studies report on pathogen-specific meningitis case fatality and the distribution of meningitis case estimates by cause. Our pneumococcal and Hib meningitis morbidity and mortality models used updated methods that are based on estimates of all-cause meningitis deaths. The methods used in this study differ from previously published subnational pneumococcal disease burden estimates.
Implications of all the available evidence
Our estimates provide insight into progress towards reducing the morbidity and mortality associated with these two pathogens in young children. These data can be used to inform policies around expanded use of the pneumococcal conjugate vaccine in India.
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All analyses were done with Stata, version 14. Our analyses are compliant with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER) statement (appendix p 4). 
Pathogen-specific pneumonia model
To estimate pathogenspecific pneumonia deaths and cases, we applied estimates of the proportion of pneu monia deaths and cases attributable to each pathogen to allcause pneumonia mortality and morbidity estimates. Allcause pneumonia deaths and cases were prepared by the WHO Maternal and Child Epidemiology Estimation collaboration (WHO/MCEE). Statelevel allcause pneu monia deaths were modelled for each year (2000-15) with verbal autopsy data from India. 7 Statelevel, allcause clinical, and severe pneumonia cases were prepared for 2000 and 2015 with a previously described risk factor prevalence model (appendix pp 10-12). 8 We used data from randomised controlled vaccine trials with various pneumonia endpoints in the probe approach to estimate the attributable fraction for each pathogen. 1 Since PCV and Hib vaccine trials did not assess vaccine efficacy against pneumonia mortality, we used efficacy against radiographconfirmed, primary end point pneumonia as a proxy for this value. The efficacy values against clinical and severe pneumonia were used to estimate pathogenspecific pneumonia morbidity. PCV and Hib vaccines do not prevent all pneumonia deaths or cases caused by pneumococcus and Hib, and so additional adjustments to vaccine efficacy values are required. To account for incomplete vaccine efficacy, the observed efficacy against vaccinetype invasive pneumo coccal disease was used as a proxy for the efficacy against vaccinetype pneumococcal pneumonia. Efficacy for vaccinetype pneumococcal pneumonia has not been measured in childhood PCV efficacy trials. PCV efficacy values were also adjusted to account for the proportion of vaccinetype invasive pneumococcal disease in the control group and for Hib vaccine use, since all trials were done in settings with routine use of this vaccine. Parameters used for these adjustments are unique to each study, and so we made these adjustments for each trial before combining estimates across trials in randomeffects metaanalyses. Given the uncertainty around the proportion of pneum onia deaths attributable to pneumococcus, we applied the same sensitivity analyses used in the estimation of global pneumococcal pneumonia deaths. 1 The primary source of uncertainty in this approach is the betweenstudy variability in vaccine efficacy estimates. Therefore, uncertainty bounds for the pathogenspecific pneumonia mortality and morbidity model were based on a jackknife analysis, in which one study is omitted from the analysis at a time, for the upper and lower bounds of the pneumococcal and Hib pneumonia fractions. 1 Other sources of uncertainty were not included in the pneumonia mortality and morbidity models.
Pathogen-specific meningitis model
Pathogenspecific meningitis deaths for each state were estimated by applying the proportion of meningitis deaths caused by pneumococcus and Hib to allcause meningitis deaths prepared by the WHO/MCEE collaboration. We estimated the proportion of meningitis deaths attributable to each pathogen in each state using summary estimates of the proportion of meningitis cases attributable to each pathogen and adjusted pathogenspecific meningitis case fatality ratios (CFR), both from values reported in the literature (appendix pp 5-9). Reported CFR estimates represent only children with access to care. Therefore, we adjusted state pathogenspecific meningitis CFR estimates using data from the National Family and Household Survey (NFHS) on the proportion of children seeking care for pneumonia symptoms, as a proxy for care seeking for meningitis (table 1) . For years missing access to care values, we assumed linear trends between available values. A 5year moving average was used to smooth pathogenspecific CFR estimates within states. State pathogenspecific meningitis mortality estimates were divided by pathogenspecific meningitis CFR estimates to derive pneumococcal and Hib meningitis morbidity estimates.
We followed previously published methods for ascer taining uncertainty bounds for meningitis morbidity and mortality; we ascertained the most conservative (ie, widest) uncertainty for aetiological proportions based on a jackknife, leaveonestudyout analysis and the reported confidence intervals from the randomeffects meta analysis. 1 As with the pneumonia models, uncertainty for the meningitis mortality and morbidity models did not account for other sources of uncertainty.
Pathogen-specific invasive non-pneumonia, non-meningitis model
We used previously described methods to estimate pathogenspecific morbidity from other NPNM invasive syndromes (eg, sepsis). 1 Briefly, we abstracted from published studies the ratio of pathogenspecific NPNM cases to pathogenspecific meningitis cases, stratified them by allcause child mortality, and within those strata we combined ratios using randomeffects metaanalyses. For each state, we applied the mortalityspecific ratio from the metaanalysis to the pneumococcal or Hib meningitis cases estimates to infer the pathogenspecific NPNM cases. Pneumococcal NPNM cases were stratified by severe and nonsevere cases by use of different NPNM case definitions from published studies. Pathogenspecific NPNM deaths were estimated with the ratio of pathogenspecific meningitis CFR to pathogenspecific NPNM CFR from the literature and by applying this value to pathogenspecific NPNM cases. Uncertainty ranges for pathogenspecific NPNM 
Population data
Sources of demographic and population data for each state are described in table 1. We used census data for India from 2001 and 2011 to estimate annual populations at risk. For years where child population data were not available, we used census data to estimate annual population growth rates to interpolate and extrapolate the statelevel child population. We then normalised popu lation data to sum to the total national UN population estimates for India. The Sample Registration System (SRS) for India was used to pre pare annual child mortality estimates for each state. 7 Since no statelevel paediatric HIV prevalence estim ates are available, we assumed the same unpublished annual national HIV prevalence from UNAIDS for each state (Mahy M, UNAIDS, personal communication).
Adjustment for Hib vaccine use
Pathogenspecific burden estimates were calculated assuming no vaccine use. We then adjusted these estimates using estimates of Hib vaccine efficacy against invasive Hib disease 18 and statespecific vaccine cov erage estimates to account for the impact of Hib vac cine use. Since no subnational estimates of Hib vac cine coverage are publicly available, we used coverage estimates for the third dose of diphtheriatetanuspertussis vaccine (DTP3) from subnational surveys, including the NFHS and the Annual Health Survey (AHS), as proxies for coverage with three doses of Hib vaccine. In the year of Hib vaccine introduction, we prorated coverage estimates to account for the month when the Hib vaccine was introduced. Linear inter polation was used when data were missing for relevant years. Our model accounts for indirect protection afforded by the Hib vaccine in the first years following introduction using the same methods previously reported. 18 We assumed no children in India received PCV before 2015, since its use in the nat ional immunisa tion programme began only in 2017 in selected states.
Reporting
India is a large and sociodemographically diverse coun try, comprising 29 states and seven union territories. For the purpose of this analysis, we used six geographic ally contiguous and socioeconomically distinct regions: north, east, northeast, central, west, and south. For state level reporting, union territories, except for Delhi, and states with fewer than 1500 total child deaths, except for Goa, have been grouped as "northeast" and "other" on the basis of their location ( reported. Reported results are rounded and reported with three significant digits or fewer; precision was not provided for fewer than 100 cases or deaths. Higher precision is provided in the appendix (pp 22-41). Morbidity and mortality estim ates, unless otherwise specified, are given for children without HIV infection. Mortality and in cidence estimates associated with pneumococcal and Hib disease among children with HIV infection are provided in the appendix (pp 22-41).
Role of the funding source
The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication. All authors had full access to all the data used in the study and the corresponding author had final responsi bility for the decision to submit for publication.
Results
Our literature review yielded only two studies that reported on the distribution of pathogens among children admitted to hospital with meningitis. 9, 10 An additional 33 studies from Asia providing data about the distribution of meningitis cases by cause were identified. We found no studies reporting on pneumococcal meningitis case fatality in India and only three studies reporting on Hib meningitis case fatality in India. [11] [12] [13] Several additional studies from epidemiologically relevant settings con tributed data to estimates of pathogenspecific meningitis case fatality (appendix pp 5-8). The literature review also yielded two studies with data about the ratio of pneumococcal NPNM cases to pneumococcal meningitis cases from India. 14, 15 In 2015, 68 700 (uncertainty range [UR] 44 600-86 000) pneumococcal deaths and 15 600 (9800-21 500) Hib deaths were estimated to have occurred in children aged 1-59 months in India. In this age group, among deaths categorised as being related to HIV/AIDS in India, we estimate that 1000 (UR 600-1200) deaths were caused by pneumococcal infection and fewer than 100 by Hib infection. At the national level, pneumococcal deaths declined by 58% (UR 22-78) since 2000, when there were 166 000 (UR 110 000-198 000) estimated pneumococcal deaths. Hib deaths declined by 81% (UR 59-91) during the same time period; in 2000, there were an estimated 82 600 (UR 52 300-112 000) Hib deaths. Despite substantial reductions in mortality, pneumococcus accounted for 14% (UR 9-17) and Hib for 3% (UR 2-4) of all deaths among children aged 1-59 months in India.
There were regional differences in pneumococcal and Hib mortality in India in 2015. Approximately 50% of pneumococcal deaths (34 100 [UR 22 100-42 700]) and 65% of Hib deaths (10 300 [6500-14 100]) were estimated to have occurred in the central region, which accounted for only 33% of the child population in that year. 75% of pneumococcal deaths (51 600 [33 400-64 600]) and 83% of Hib deaths (13 000 [8100-17 800]) in 2015 occurred in the eight EAG states and Assam, which together account for 55% of the child population younger than 5 years. The northeast region had the highest estimated To be able to compare our findings with other published pneumococcal mortality estimates, we estimated there were 76 700 (UR 54 400-79 900) pneumococcal pneumo nia deaths, 11 800 (5600-22 700) meningitis deaths, and 7200 (3400-13 800) NPNM deaths in children aged 1-59 months in 2010. Of the estimated Hib deaths in the same year, 74% (11 600 [UR 8200-15 300]) were due to pneumonia, 25% (4000 [1600-6100]) due to meningitis, and less than 1% (<100) due to NPNM. 13 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) Rates are cases or deaths per 100 000 children aged 1-59 months. NPNM=non-pneumonia, non-meningitis. UR=uncertainty range. *Burden among children with HIV infection included in the appendix (pp 22-41). As previously reported, 1 we estimated pneumococcus to account for 34% (UR 24-36) and Hib to account for 21% (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) of radiographconfirmed pneumonia cases; we used those casederived proportions as a proxy for the fraction of pneumonia deaths attributable to these two pathogens, in settings where PCV and Hib vaccine are not used. 1 Our sensitivity analysis found that the proportion of radiographconfirmed pneumonia that is pneumococcus could be as high as 51% (UR 15-87), in which case there could have been as many as 102 000 (UR 62 200-110 000) estimated pneumococcal pneumonia deaths and therefore 118 000 (69 000-140 000) pneumococcal deaths in 2015. Statelevel pneumococcal pneumonia deaths based on this sensitivity analysis are provided in the appendix (pp 42-57).
We estimated 1·6 million (UR 1·2-1·9) cases of severe pneumococcal disease (ie, severe pneumococcal pneu monia, pneumococcal meningitis, and severe NPNM) in 2015. There were 2·7 million (UR 2·0 By 2015, severe Hib disease had declined in India to 236 000 cases (UR 138 000-468 000), a substantial decline from the 883 000 (517 000-1 750 000) estimated cases in 2000. More than 73% of severe Hib cases in 2015 occurred in three states that together only accounted for 30% of the child population in that same year: Uttar Pradesh (UR 120 000 [703 000-238 000]), Maharashtra (39 000 [22 900-78 200]), and Odisha (13 600 [7900-27 100]).
Discussion
We estimated the comprehensive (ie, including all relevant syndromes) subnational pneumococcal and Hib morbidity and mortality burden for children aged 1-59 months in India. Our analysis found that, even before introduction of the PCV or Hib vaccine, pneumococcal and Hib deaths in children had declined substantially since 2000. Despite sub stantial reductions in mortality, pneumococcus accoun ted for 14% (UR [9] [10] [11] [12] [13] [14] [15] [16] [17] and Hib for 3% (UR 2-4) of all deaths among children aged 1-59 months in India. These deaths are largely preventable with specific interventions such as vaccines that prevent the occurrence of causespecific disease and with early and effective treatment. These estimates can be used to monitor progress towards achieving child survival targets and inform the impact of disease prevention and treatment strategies.
The reduction in deaths from these two pathogens before the introduction and widespread use of the PCV and Hib vaccine reflects overall child survival trends in India during this period. 19 The launch of the National Rural Health Mission (NRHM) in 2005, now the National Health Mission (NHM), has helped to expand and improve primary maternal and child health services in the country, which is likely to have contributed to improvements in overall child survival. 20, 21 Our model quantified the accelerated decline in Hib deaths after 2012, during which the Hib vaccine was introduced in many states. Uttar Pradesh, which accounted for approximately 60% of Hib deaths, was the last state to initiate routine use of the Hib vaccine in December, 2015.
A disproportionate number of pneumococcal and Hib deaths continue to occur in states located in the eastern and central regions. The states in these two regions, excluding West Bengal, comprise the EAG states. Dis parities between EAG states (inclusive of Assam) and nonEAG states, represented by the difference be tween pneu mococcal and Hib mortality between these two groups, diminished between 2000 and 2015. The NHM's efforts have been most intensive in EAG states and in states in the northeast region, including Assam. This is likely to have contributed to a reduction in these disparities over time. The estimates imply that introduction of the Hib vaccine in many EAG states and Assam throughout 2014 and 2015 has contributed to further minimisation of the differences in Hib mortality rates between these two groups of states (figure 1). The recent subnational introduction of PCV13 in 2017 and its projected national rollout over the coming years is expected to further reduce differences in pneumococcal and allcause mortality.
Similar to global burden estimates, pneumonia domin ated the syndromic distribution of deaths associated with pneumococcus and Hib in India. As a result, disease burden estimates for both pathogens are highly sensitive to changes in estimates for allcause pneumonia mortality and the fraction of pneumonia deaths associated with each pathogen. In the probe approach, we used estimates of the proportion of radiograph confirmed pneumonia cases caused by pneumococcus and Hib as proxy values for the proportion of pneumonia deaths associated with each pathogen. This approach results in the inherent inference that the case fatality estimates for radiographconfirmed pneumonia caused by pneumococcus, Hib, and nonpneumococcus or non Hib are identical, which is likely to be incorrect. Without access to timely and effect ive antibiotics, the case fatality for bacterial causes of pneumonia is likely to be higher than that for nonbacterial pneumonia. Most deaths from pneumonia in India occur in the community, rather than in healthcare facilities, indicating that many individuals who develop pneumonia probably do not have access to antibiotics. 22 As a result, our approach has a direction of bias that is likely to underestimate state level mortality rates and deaths from pneumococcal and Hib pneumonia. The vaccine probe approach also requires adjustment for incomplete vaccine efficacy. As a proxy for vaccine type pneumococcal pneumonia efficacy in children, we used efficacy against vaccinetype invasive pneumococcal diseases, which is likely to be higher than vaccinetype pneumococcal pneumonia efficacy. If true, this approach also underestimates the contribution of pneumococcus to deaths from pneumonia. We did a sensitivity analysis using data from a PCV clinical trial with a pathogen specific pneumonia efficacy outcome done in an elderly population in the Netherlands 23 to assess the magnitude of potential underestimation. We found that deaths from pneumococcal pneumonia could be as much as 50% higher than our current estimates. 1 Others have included this adjustment in their base case model for global pneumococcal pneumonia mortality estimates; 24 we report the results of our sensitivity analysis at the state level in the appendix (pp 42-57).
Our subnational model allows us to account for differences in vaccine coverage between states. Without accounting for subnational differences in vaccine cov erage, the impact of new vaccines on pathogenspecific disease would be biased. In the case of the Hib vaccine, which was first used in states with low child mortality, accounting for vaccine use at the state level restricts the degree to which the effects of the Hib vaccine are overestimated in the years following the introduction of vaccine. We used statelevel DTP3 coverage from two different surveys as a proxy for statelevel Hib vaccine coverage. In the routine immunisation programme in India, the Hib vaccine is delivered together with four other antigens (ie, DTP and hepatitis B) as a pentavalent vaccine.
The 13valent PCV was introduced in 2017 in three states with relatively high child mortality. Researchers who did an invasive pneumococcal disease surveillance study between 2011 and 2015 in India concluded that the 13valent PCV product includes serotypes responsible for 74% of invasive pneumococcal disease nationwide. 25 Although subnational PCV coverage estimates in the private sector have been published for 2012, 26 we did not use these estimates in our model as the overall national coverage was reported to be lower than 1%. Additionally, those who received PCV in the private sector are probably already at low risk of pneumococcal disease and mortality than those without access to PCV in the private sector.
Subnational pneumococcal pneumonia morbidity and mortality burden estimates for 2010 have been published. 6 We prepared annual estimates of subnational pneumo coccal and Hib deaths by syndrome between 2000 and 2015 so that we could compare our estimates with the published literature. In 2010, we estimated there were 76 700 (UR 54 400-79 900) deaths from pneumococcal pneumonia in Indian children aged 1-59 months (appendix pp 29-34), whereas Farooqui and colleagues 6 estimated 105 100 (UR 91 100-120 000) deaths from pneumococcal pneumonia. Although there are quanti tative differences between our estimates and those of Farooqui and colleagues 6 at the state level, the rank order of states based on deaths from pneumococcal pneumonia is similar across the two models (ie, the four states with the greatest burden are the same in both models), indicating that the use of either set of estimates for state specific PCV prioritisation would lead to the same conclusions. The conceptual approaches used to prepare estimates of pneumococcal pneumonia deaths differ between the two models, which largely account for the quantita tive discrepancies between the estimates prepared by Farooqui and colleagues and our estimates. A statelevel comparison of results from both models and the details of the different approaches is provided in the appendix (p 20).
India has previously introduced new vaccines into the national immunisation programme in a phased manner. The approach for state selection has differed by vaccine, and decision makers might consider a range of factors for which subnational data are available, including disease burden, potential vaccine impact, indicators of equity, healthsystem readiness, and routine immunisation cov er age. India has usually initiated introductions in states and union territories with relatively strong health systems. However, the introduction of PCV marked a shift in this approach, prioritising on the basis of child mortality rather than healthsystem strength or vaccine coverage. The availability of subnational estimates enables evidence based strategies for state prioritisation; in particular, such estimates allow India to develop equityfocused and impactfocused approaches to PCV rollout and subsequent new vaccine introductions.
Policy makers increasingly consider mortality and mor bidity burden estimates together when making decisions about the introduction of new vaccines. Mor bidity burden estimates are also important variables in vaccine cost effectiveness analyses. 27 Until now, sub national morbidity burden estimates for pneumococcus have only been available for severe pneumonia. Although this syndrome accounts for a large fraction of severe pneumococcal diseases, bacterial meningitis cases in India often result in severe, longterm neurological impairments. 28, 29 These morbidity burden estimates are necessary for costof illness assessments. To contribute to these efforts, we prepared subnational pneumococcal and Hib morbidity estimates for each syndrome associated with these pathogens.
In addition to the challenges associated with the vaccine probe approach described above, our approach for estim ating the subnational burden of pneumococcal and Hib disease in India has other limitations. Although our estimates inherently account for statelevel disease risk factors and access to care differences, additional dis parities within states and populations remain. Our models do not account for these disparities. Allcause child mortality estimates are now available with higher spatial resolution (ie, at the district level). 30 These estim ates could serve as the basis for future pathogenspecific mortality estimates at the district level in India. However, such estimates would require additional districtlevel input data, including PCV and Hib vaccine coverage. This information would be useful for future pneumococcal disease burden estimates, given the districtwise intro duction strategy for PCV.
Another limitation of our model is the continued reliance on verbal autopsy data for allcause pneumonia and meningitis deaths. 7 Verbal autopsy data are susceptible to misclassification and other challenges that have been described extensively. 31, 32 These challenges are especially relevant for deaths from nonspecific syndromes such as pneumonia. Nationally representative causeofdeath data that have been directly measured, as opposed to modelled estimates, are now available. 33 Pneumococcal and Hib disease burden estimates based on these causeofdeath data could complement the estimates provided here. Additionally, strengthened vital registration systems and medical cause of death reporting in India would help improve confidence in causespecific disease burden estimates.
We used data from India or its regional neighbours wherever possible. Populationatrisk and demographic data came largely from Indian Government sources. The pathogenspecific pneumonia models use data from vaccine clinical trials done in several countries around the world. The implications, assumptions, and possible consequential underestimation or overestimation from the pathogenspecific component of the model are discussed elsewhere. 1 Another limitation of our estimates is the absence of data from India about pathogenspecific meningitis and NPNM. We therefore relied on data from studies done in geographically and epidemiologically relevant settings. Additional pathogenspecific data from observational studies done in India would help improve disease burden estimates.
Our subnational estimates of mortality and morbidity caused by pneumococcus and Hib suggest that India has made substantial progress in reducing mortality and morbidity from these diseases in the past 15 years and that the recent Hib vaccine introductions have further accelerated these reductions. The introduction and ex panded use of these vaccines as planned by the govern ment has the potential to substantially accelerate the reduction of childhood pneumococcal and Hib mor bidity and mortality towards meeting the Sustainable Development Goal child survival targets by 2030.
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